Time to Testosterone Recovery Varies With ADT Duration
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 10, 2024 -- For men receiving androgen deprivation therapy (ADT) for prostate cancer, time to testosterone recovery (TR) varies with ADT duration, according to a study published online Sept. 19 in European Urology.
Wee Loon Ong, M.B.B.S., from Monash University in Melbourne, Australia, and colleagues obtained individual patient data from randomized controlled trials of radiotherapy with ADT and prospectively collected serial testosterone data to examine the oncological impact of an effective castration period in patients receiving definitive radiotherapy and ADT for prostate cancer. For each prescribed ADT duration, the times to noncastrate TR (>1.7 nmol/l) and nonhypogonadal TR (>8.0 nmol/l) were estimated, and corresponding nomograms were developed. The analysis included 1,444 men from five trials, of whom 115 received four months, 880 received six months, 353 received 18 months, 36 received 28 months, and 60 received 36 months of ADT.
The researchers found considerable variation in times to noncastrate TR and nonhypogonadal TR by ADT duration. A higher likelihood of TR was seen for higher baseline testosterone and younger age. There was a nonlinear association for effective castration period with metastasis-free survival for any ADT duration. The optimal castration period for a metastasis-free survival benefit was 10.6 and 18 months for men who received six and 18 months of ADT, respectively.
"An understanding of TR kinetics is critical for counseling of men who are starting ADT so that they have realistic expectations regarding the likely time to resolution of ADT-related side effects," the authors write.
Several authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Opportunistic Community Screening IDs Uncontrolled Cardiovascular Risk Factors
FRIDAY, Aug. 15, 2025 -- Opportunistic pop-up community screening identifies a high prevalence of uncontrolled cardiovascular risk factors, according to a study published online...
Missed Opportunity Common in Patients With High-Grade Serous Ovarian Cancer
FRIDAY, Aug. 15, 2025 -- A considerable proportion of patients with high-grade serous cancer (HGSC) have missed opportunities for risk assessment with genetic testing and for...
EHR Notes Reveal Potential Racial Bias in Doctors' Perception of Patient Credibility
FRIDAY, Aug. 15, 2025 -- An analysis of more than 13 million electronic health record (EHR) notes shows potential racial bias in how doctors document patient trustworthiness...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.